TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals announced that its CEO, Dr. Howie McKibbon, will present at the Canaccord Drug and Device Healthcare Conference in Noosa. The presentation aims to engage institutional investors and is part of a broader investor roadshow hosted by Canaccord Genuity. This event is significant as it provides Botanix an opportunity to showcase its FDA-approved product, Sofdra®, and potentially strengthen its market position and investor relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US. The company has received FDA approval for its lead product, Sofdra®, which is the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel solution for patients with this condition.
Average Trading Volume: 8,802,218
Technical Sentiment Signal: Sell
Current Market Cap: A$285.7M
See more data about BOT stock on TipRanks’ Stock Analysis page.